{{Rsnum
|rsid=9345389
|Gene=TSG1
|Chromosome=6
|position=93730886
|Orientation=plus
|GMAF=0.118
|Gene_s=GNL1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 96.5 | 3.5 | 0.0
| HCB | 56.2 | 36.5 | 7.3
| JPT | 54.0 | 38.1 | 8.0
| YRI | 79.6 | 17.7 | 2.7
| ASW | 73.7 | 26.3 | 0.0
| CHB | 56.2 | 36.5 | 7.3
| CHD | 58.7 | 38.5 | 2.8
| GIH | 90.1 | 9.9 | 0.0
| LWK | 69.1 | 29.1 | 1.8
| MEX | 77.6 | 20.7 | 1.7
| MKK | 81.4 | 17.9 | 0.6
| TSI | 99.0 | 1.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9345389
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.05, combined P value= 1.12E-04. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470187
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9345389
|overall_frequency_n=11
|overall_frequency_d=126
|overall_frequency=0.0873016
|n_genomes=11
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}